Inbox Robot: Immunotherapy News http://www.inboxrobot.com/news/immunotherapyConstantly updated news and information about a variety of topics. Vaccine To Prevent Kidney Cancer Recurrence Not Shown To Be Effective http://www.inboxrobot.com/news.php?fid=177209664 5 Jul 2008 07:35 GMT ... MD, USA), cautions that some researchers and companies can weaken the results of cancer immunotherapy studies because they dislike or disagree with the results of randomized clinical trials. In ... Nordic breast cancer vacc shows strong data http://www.inboxrobot.com/news.php?fid=177160183 4 Jul 2008 18:55 GMT ... Nordic breast cancer vacc shows strong data BN ImmunoTherapeutics, Danish drugmaker Bavarian Nordic's cancer research unit, has completed an interim analysis of two ... Pipeline Insight - Cancer Overview - Increasing diversity offers both high risk and reward - http://www.inboxrobot.com/news.php?fid=177147084 4 Jul 2008 16:35 GMT ... cover a vast array of anticancer drug classes, including antihormonal therapies, cytotoxics, gene therapies, immunotherapies, photodynamic therapies, radiotherapeutics, targeted therapies and therapeutic vaccines. The late-phase pipeline contains equal amounts ... 3rd ESU Masterclass Presents Insightful Updates On Urological Oncology http://www.inboxrobot.com/news.php?fid=177114151 4 Jul 2008 11:34 GMT ... suppression than after GnRH-agonists treatment. GnRH agonists failed to achieve castration levels of testosterone. Immunotherapy and vaccines were the topics of Prof Peter Mulders lecture, which opened the second ... Hepatitis C Vaccine Delivered By Inovio Biomedical's Electroporation System Shows Increased T-Cell Responses And Reduced Viral Loads, Study http://www.inboxrobot.com/news.php?fid=177114144 4 Jul 2008 11:34 GMT ... 2012. About Inovio Biomedical Corporation Inovio Biomedical (AMEX:INO) is focused on developing multiple DNA-based immunotherapies and DNA vaccines. Inovio is a leader in developing human applications of electroporation using ... Antigenics kidney cancer vaccine shows no increased survival in trial - study http://www.inboxrobot.com/news.php?fid=177093240 4 Jul 2008 06:58 GMT ... expectations. Selectively highlighting partial findings weakens the credibility of the nascent field of cancer immunotherapy, he said. jlw Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, ... Multitargeted Immune Therapy Scores Well for Severe Lupus Nephritis http://www.inboxrobot.com/news.php?fid=177079614 4 Jul 2008 04:36 GMT Introgen Reduces Development Staff to Focus on Commercial Activities after ADVEXIN Regulatory Filings in U.S. http://www.inboxrobot.com/news.php?fid=177052845 3 Jul 2008 23:30 GMT ... therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using ... Kidney Cancer Vaccine Shows No Boost in Survival http://www.inboxrobot.com/news.php?fid=177052222 3 Jul 2008 23:30 GMT ... and being permitted to draw the target afterwards," he wrote. The field of cancer immunotherapy is weakened when some researchers and vaccine companies are reluctant to accept the results ... Kidney cancer vaccine falls short in clinical trial: study http://www.inboxrobot.com/news.php?fid=177052141 3 Jul 2008 23:30 GMT ... meet their highlighting partial findings weakens the credibility of the nascent field of cancer immunotherapy, he said. ... Introgen Reduces Development Staff to Focus on Commercial Activities after ADVEXIN Regulatory Filings in U.S. and Europe http://www.inboxrobot.com/news.php?fid=177042124 3 Jul 2008 21:54 GMT ... therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using ... Investigators at Institute for Microbiology zero in on non-small cell lung cancer therapy http://www.inboxrobot.com/news.php?fid=177039057 3 Jul 2008 21:19 GMT ... lung cancer (NSCLC) patients with stage II and III/IV were enrolled and 49 completed immunotherapy. Patients were grouped based on immunosuppressive acidic protein (IAP)," scientists in Sendai, Japan report. ... Oxford Biomedica Responds t... http://www.inboxrobot.com/news.php?fid=176989172 3 Jul 2008 15:19 GMT ... for Bavarian Nordic," he continued. Oxford BioMedica is a biopharmaceutical company specializing in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford ... Phase III ARISER Study with Rencarex: Patient Recruitment Successfully Completed http://www.inboxrobot.com/news.php?fid=176979287 3 Jul 2008 13:59 GMT ... reflect future events or developments. The international, multicentre, randomised trial called ARISER (Adjuvant RENCAREX Immunotherapy trial to Study Efficacy in non-metastasised Renal cell carcinoma) examines the efficacy of the ... Phase II Results For Low-Dose Oral Immune Tolerance Therapy (ARG201) In Systemic Scleroderma Published http://www.inboxrobot.com/news.php?fid=176962582 3 Jul 2008 11:53 GMT ... autoimmune disease causing widespread fibrosis of the skin and internal organs. ARG201 is an immunotherapy that induces low dose oral immune tolerance in SSc patients causing downregulation of the ...